We can therefore postulate that in the CLL low group, mostly with unmutated IGHV, the good response to ibrutinib is attributable to the cell shut down secondary to the deactivation of the BTK signaling, suggesting that these cells are addicted to this signaling for their survival. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.